<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: Observational and mechanistic studies have suggested a possible relationship between treatment with <z:chebi fb="0" ids="6801">metformin</z:chebi> and decreased incidence of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in participants with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We extracted data for <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> from the ADOPT (A <z:mp ids='MP_0002055'>Diabetes</z:mp> Outcome Progression Trial) and RECORD (<z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in <z:mp ids='MP_0002055'>Diabetes</z:mp>) randomised controlled clinical trials, in which the efficacy and/or safety of <z:chebi fb="0" ids="6801">metformin</z:chebi> was assessed in comparison with <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> and <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: <z:hpo ids='HP_0002664'>Neoplasm</z:hpo> occurrences were collected as adverse events in these studies </plain></SENT>
<SENT sid="3" pm="."><plain>We reviewed and re-analysed the individual participant data in both studies for serious adverse events, <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> reported as adverse events and related <z:hpo ids='HP_0002664'>neoplasms</z:hpo> of special interest </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In ADOPT, 50 participants (3.4%) on <z:chebi fb="0" ids="6801">metformin</z:chebi> and 55 (3.8%) on each of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> and <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> (known as <z:chebi fb="0" ids="5441">glyburide</z:chebi> in the USA and Canada) developed serious adverse event <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> (excluding non-<z:hpo ids='HP_0002861'>melanoma</z:hpo> <z:e sem="disease" ids="C0007114" disease_type="Neoplastic Process" abbrv="">skin cancers</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>This corresponds to 1.03, 1.12 and 1.31 per 100 person-years, giving hazard ratios for <z:chebi fb="0" ids="6801">metformin</z:chebi> of 0.92 (95% CI 0.63-1.35) vs <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> and 0.78 (0.53-1.14) vs <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>In RECORD, on a background of <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi>, 69 (6.1%) participants developed malignant <z:hpo ids='HP_0002664'>neoplasms</z:hpo> in the <z:chebi fb="0" ids="6801">metformin</z:chebi> group, compared with 56 (5.1%) in the <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> group (HR 1.22 [0.86-1.74]) </plain></SENT>
<SENT sid="7" pm="."><plain>On a background of <z:chebi fb="0" ids="6801">metformin</z:chebi>, 74 (6.7%) participants in the <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> group developed malignant <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, compared with 57 (5.1%) in the <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> group (HR 1.33 [0.94-1.88]) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS/INTERPRETATION: The <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> rates in these two randomised controlled clinical trials do not support a view that <z:chebi fb="0" ids="6801">metformin</z:chebi> offers any particular protection against <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> compared with <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>However, they do not refute the possibility of a difference compared with <z:chebi fb="0" ids="26831">sulfonylureas</z:chebi> </plain></SENT>
</text></document>